BACKGROUND: Hyperhomocysteinemia has been associated with a higher risk of cardiovascular disease (CVD) in epidemiological studies, but recent trials have failed to show a benefit of lowering homocysteine. To address this apparent paradox, we explored whether interaction between genetic and dietary factors related to homocysteine metabolism contributes to CVD risk. METHODS: We evaluated the associations of homocysteine, methylenetetrahydrofolate reductase (MTHFR) 677C>T genotype, and dietary intake of folate/B-vitamins with subsequent CVD events in 24 968 apparently healthy white American women followed for 10 years. Plasma homocysteine was measured using an enzymatic assay. MTHFR genotype was determined with a multiplex PCR using biotinylated primers. RESULTS: In unadjusted analyses, homocysteine showed moderately strong linear associations with CVD, with hazard ratios (95% CI) comparing top with bottom quintiles for total CVD of 1.92 (1.55-2.37), myocardial infarction 2.32 (1.52-3.54), and ischemic stroke 2.25 (1.45-3.50), all P(trend) <0.001. These ratios were markedly attenuated after adjusting for traditional risk factors and socioeconomic status to 1.08 (0.86-1.36), P(trend) = 0.12; 1.20 (0.76-1.87), P(trend) = 0.14; and 1.21 (0.75-1.94), P(trend) = 0.50, respectively. Homocysteine was associated with MTHFR genotype (1.4 micromol/L higher homocysteine for TT vs CC, P <0.001) and inversely with intake of folate, vitamin B(2), B(6), and B(12), all P(trend) <0.001. However, there was no association of MTHFR genotype or dietary folate/B-vitamins with CVD. In addition, there were no gene-diet or gene-homocysteine interactions in relation to CVD. CONCLUSIONS: In this large-scale prospective study, the association of homocysteine with CVD was markedly attenuated after adjusting for risk factors and was not modified by MTHFR 677C>T or intake of folate or B-vitamins.
BACKGROUND:Hyperhomocysteinemia has been associated with a higher risk of cardiovascular disease (CVD) in epidemiological studies, but recent trials have failed to show a benefit of lowering homocysteine. To address this apparent paradox, we explored whether interaction between genetic and dietary factors related to homocysteine metabolism contributes to CVD risk. METHODS: We evaluated the associations of homocysteine, methylenetetrahydrofolate reductase (MTHFR) 677C>T genotype, and dietary intake of folate/B-vitamins with subsequent CVD events in 24 968 apparently healthy white American women followed for 10 years. Plasma homocysteine was measured using an enzymatic assay. MTHFR genotype was determined with a multiplex PCR using biotinylated primers. RESULTS: In unadjusted analyses, homocysteine showed moderately strong linear associations with CVD, with hazard ratios (95% CI) comparing top with bottom quintiles for total CVD of 1.92 (1.55-2.37), myocardial infarction 2.32 (1.52-3.54), and ischemic stroke 2.25 (1.45-3.50), all P(trend) <0.001. These ratios were markedly attenuated after adjusting for traditional risk factors and socioeconomic status to 1.08 (0.86-1.36), P(trend) = 0.12; 1.20 (0.76-1.87), P(trend) = 0.14; and 1.21 (0.75-1.94), P(trend) = 0.50, respectively. Homocysteine was associated with MTHFR genotype (1.4 micromol/L higher homocysteine for TT vs CC, P <0.001) and inversely with intake of folate, vitamin B(2), B(6), and B(12), all P(trend) <0.001. However, there was no association of MTHFR genotype or dietary folate/B-vitamins with CVD. In addition, there were no gene-diet or gene-homocysteine interactions in relation to CVD. CONCLUSIONS: In this large-scale prospective study, the association of homocysteine with CVD was markedly attenuated after adjusting for risk factors and was not modified by MTHFR 677C>T or intake of folate or B-vitamins.
Authors: Shannon D Barker; Sherri Bale; Jessica Booker; Arlene Buller; Soma Das; Kenneth Friedman; Andrew K Godwin; Wayne W Grody; Edward Highsmith; Jeffery A Kant; Elaine Lyon; Rong Mao; Kristin G Monaghan; Deborah A Payne; Victoria M Pratt; Iris Schrijver; Antony E Shrimpton; Elaine Spector; Milhan Telatar; Lorraine Toji; Karen Weck; Barbara Zehnbauer; Lisa V Kalman Journal: J Mol Diagn Date: 2009-09-18 Impact factor: 5.568
Authors: Karin B Nelson; Amanda Kalaydjian Richardson; Jianping He; Tarranum M Lateef; Suzan Khoromi; Kathleen R Merikangas Journal: Arch Pediatr Adolesc Med Date: 2010-04
Authors: Hannah C Cox; Rod A Lea; Claire Bellis; Melanie Carless; Thomas D Dyer; Joanne Curran; Jac Charlesworth; Stuart Macgregor; Dale Nyholt; Daniel Chasman; Paul M Ridker; Markus Schürks; John Blangero; Lyn R Griffiths Journal: Neurogenetics Date: 2012-06-08 Impact factor: 2.660
Authors: David Conen; Suzanne Cheng; Lori L Steiner; Julie E Buring; Paul M Ridker; Robert Y L Zee Journal: J Hypertens Date: 2009-03 Impact factor: 4.844
Authors: Michelle A Albert; Guillaume Pare; Alanna Morris; Lynda Rose; Julie Buring; Paul M Ridker; Robert Y L Zee Journal: Am Heart J Date: 2009-04 Impact factor: 4.749
Authors: Guillaume Paré; Daniel I Chasman; Alexander N Parker; Robert R Y Zee; Anders Mälarstig; Udo Seedorf; Rory Collins; Hugh Watkins; Anders Hamsten; Joseph P Miletich; Paul M Ridker Journal: Circ Cardiovasc Genet Date: 2009-04